Lineage Cell Therapeutics
LCTX
113 hedge funds and large institutions have $94.2M invested in Lineage Cell Therapeutics in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 11 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 26
0.46% more ownership
Funds ownership: 49.56% → 50.01% (+0.46%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 116 → 113 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
32% less capital invested
Capital invested by funds: $138M → $94.2M (-$44.1M)
Top Buyers
| 1 |
RA
Raffles Associates
New York
|
+$1.27M |
| 2 |
BlackRock
New York
|
+$1.18M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$712K |
| 4 |
State Street
Boston,
Massachusetts
|
+$426K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$379K |
Top Sellers
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.71M |
| 2 |
PGP
Prescott General Partners
Boca Raton,
Florida
|
-$1.36M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$692K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$244K |
| 5 |
Squarepoint
New York
|
-$163K |
LCTX Hedge Fund Activity: Q2 2024 in Review
113 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2024, worth a combined $94.2M — down 32% from $138M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LCTX and 8 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 35 added.
The largest buyer was Raffles Associates, adding an estimated $1.27M. The largest seller was Logos Global Management, cutting an estimated $1.71M.
- 113 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2024, down from 116 in Q1 2024.
- Funds reported $94.2M of Lineage Cell Therapeutics stock for Q2 2024, down 32% quarter-over-quarter.
- 8 funds opened new Lineage Cell Therapeutics positions in Q2 2024 and 11 closed out, a net change of -3 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2024 was Raffles Associates, an estimated $1.27M added.
- The largest Lineage Cell Therapeutics seller in Q2 2024 was Logos Global Management, an estimated $1.71M sold.
Based on aggregated 13F filings for Q2 2024.